GPT and steatosis: performed WES on 46,544 Americans and found that the HSD17B13 LOF mutation (rs72613567:TA) was associated with chronic liver disease,213 risk of progression from steatosis to steatohepatitis, and reduced plasma alanine aminotransferase (ALT) and glutamate aminotransferase (AST) levels, and also revealed that the variant was negatively associated with chronic liver disease in an allelic dose‐dependent manner.213